Mavyret (glecaprevir and pibrentasvir)
What is Mavyret?
In August 2017 the U.S. Food and Drug Administration approved the prescription medication Mavyret™ (glecaprevir and pibrentasvir). Mavyret is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis. MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
The active ingredients per tablet of Mavyret are 100 mg glecaprevir and 40 mg pibrentasvir.
Last Updated: October 2017
"FDA approves Mavyret for Hepatitis C." FDA.gov. U.S. Food & Drug Administration. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm. Retrieved October 6, 2017.
"Highlights of Prescribing Information." Rxabbvie.com. AbbVie Inc., http://www.rxabbvie.com/pdf/mavyret_pi.pdf. Retrieved October 6, 2017.
"Mavyret Product Summary." Mavyret.com. AbbVie Inc., https://www.mavyret.com/content/dam/abbvie-mavyret-brand/product-summary.pdf. Retrieved October 6, 2017.
"Introducing MavyRet." Mavyret.com. AbbVie Inc., www.mavyret.com. Retrieved October 6, 2017.